“The best way to create access right now is to go through the drug development process and have [psychedelic-assisted therapies] approved by the FDA,” Amy Emerson, CEO of MAPS Public Benefit …
Harvard Law Today covers the launch of the Project on Psychedelics Law and Regulation (POPLAR) at Harvard Law School’s Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics. “We …
All stakeholders at the Multidisciplinary Association for Psychedelic Studies (MAPS) and MAPS Public Benefit Corporation (MAPS PBC) are committed to providing quality and comprehensive training and supervision …
In August 2021, MAPS raised $1,705,031 in donations and pledges from over 1,400 supporters. Of this amount: $782,969 is for MDMA-related projects; $451,685 is for general support; $300,010 is for health …
Over 300 clinicians and counselors just completed the 4 month MDMA Therapy Training Program online course. Congratulations! This cohort represented the largest of its kind and is part of an effort to train …
Frontiers in Psychiatry has published a review article summarizing research on disruptions in neurological, perceptual, receptive, and expressive systems regulating social behavior in SAD and proposing …
California Senate Bill SB 519, authored by Senator Scott Wiener (D-San Francisco), was put on hold and will now become a two-year bill. The legislation that would decriminalize several psychedelic substances …
On August 17 and 18, 2021, researchers from MAPS Public Benefit Corporation (MAPS PBC) conducted the official site initiation visit for the MAPS-sponsored Phase 2 study of MDMA-assisted therapy for U.S. …
Celebrate National Hispanic Heritage Month by expressing gratitude for Hispanic and Latinx visionaries, researchers, community members, and others who have expanded awareness about psychedelics. Taking …
MAPS is sponsoring a single-site, open-label Phase 2 study designed to test the feasibility of administering MDMA in conjunction with psychotherapy for combat-related treatment-resistant PTSD in U.S. military …
We are currently seeking research volunteers for our second Phase 3 clinical trial of MDMA-assisted therapy for PTSD. Volunteers must have PTSD and live in an area close to a study site. Volunteers will …
On Friday, September 10, 2021, researchers from MAPS Public Benefit Corporation (MAPS PBC) conducted the official site initiation visit for the cross-over extension study for MAPS-sponsored Phase 3 trials …
